Recorlev Normalizes Cortisol Levels in LOGICS Trial: Results Published
Recorlev (levoketoconazole) outperformed a placebo at normalizing urine cortisol levels among people with endogenous Cushing’s syndrome in the Phase 3 LOGICS trial. Top-line data from the study were announced in 2020. Full results have now been published in Pituitary in the study, “Levoketoconazole in the treatment…